AMC MCQ → Infectious diseases
Infectious diseases accounts for roughly 2% of the AMC MCQ blueprint. This bank has 116 items tagged to it.
Around 2% of the paper, per AMC examination specifications and clinical handbook. That weighting is why the DocPasser mock builder samples sections in proportion rather than shuffling everything into one pile — practising a flat distribution trains you for a paper that does not exist.
A 29 year old man presents with five days of high fever, shaking chills, drenching sweats, headache and muscle aches, two weeks after returning from a month in rural sub-Saharan Africa. He took no antimalarial prophylaxis. He is febrile with a palpable spleen but is alert and haemodynamically stable, and his thick and thin films show Plasmodium falciparum at a low parasite count. What is the most likely diagnosis?
The point: Malaria must be considered in any febrile traveller returning from an endemic area, and the single most important rule is that fever after travel is malaria until proven otherwise. It is caused by Plasmodium species transmitted by mosquitoes; Plasmodium falciparum is the dangerous one, capable of causing severe, rapidly fatal disease, and it usually presents within a month of return, while Plasmodium vivax and ovale can relapse months later from dormant liver forms. The presentation is non-specific: fever, often but not always cyclical, with chills, rigors, sweats, headache, myalgia, and sometimes diarrhoea or jaundice, and examination may show only fever and splenomegaly. The diagnosis rests on thick and thin blood films for the parasite and species with a parasite count, repeated up to three times if the first is negative, supported by rapid antigen tests. Severe falciparum malaria is defined by impaired consciousness, shock, acidosis, hypoglycaemia, severe anaemia, renal failure, pulmonary oedema or a high parasite count, and it is treated as an emergency with parenteral artesunate. Uncomplicated malaria is treated with an appropriate oral regimen by species and resistance, and vivax and ovale need additional treatment to clear the liver stage after checking for G6PD deficiency. Prevention is by bite avoidance and chemoprophylaxis.
Source: Therapeutic Guidelines (Australia) — Antibiotic: malaria Therapeutic Guidelines (Australia) · tier 3, national formulary
A 29 year old man presents with five days of high fever, shaking chills, drenching sweats, headache and muscle aches, two weeks after returning from a month in rural sub-Saharan Africa. He took no antimalarial prophylaxis. He is febrile with a palpable spleen but is alert and haemodynamically stable, and his thick and thin films show Plasmodium falciparum at a low parasite count. What is the most appropriate initial investigation?
The point: Malaria must be considered in any febrile traveller returning from an endemic area, and the single most important rule is that fever after travel is malaria until proven otherwise. It is caused by Plasmodium species transmitted by mosquitoes; Plasmodium falciparum is the dangerous one, capable of causing severe, rapidly fatal disease, and it usually presents within a month of return, while Plasmodium vivax and ovale can relapse months later from dormant liver forms. The presentation is non-specific: fever, often but not always cyclical, with chills, rigors, sweats, headache, myalgia, and sometimes diarrhoea or jaundice, and examination may show only fever and splenomegaly. The diagnosis rests on thick and thin blood films for the parasite and species with a parasite count, repeated up to three times if the first is negative, supported by rapid antigen tests. Severe falciparum malaria is defined by impaired consciousness, shock, acidosis, hypoglycaemia, severe anaemia, renal failure, pulmonary oedema or a high parasite count, and it is treated as an emergency with parenteral artesunate. Uncomplicated malaria is treated with an appropriate oral regimen by species and resistance, and vivax and ovale need additional treatment to clear the liver stage after checking for G6PD deficiency. Prevention is by bite avoidance and chemoprophylaxis.
Source: Therapeutic Guidelines (Australia) — Antibiotic: malaria Therapeutic Guidelines (Australia) · tier 3, national formulary
A 29 year old man presents with five days of high fever, shaking chills, drenching sweats, headache and muscle aches, two weeks after returning from a month in rural sub-Saharan Africa. He took no antimalarial prophylaxis. He is febrile with a palpable spleen but is alert and haemodynamically stable, and his thick and thin films show Plasmodium falciparum at a low parasite count. What is the most appropriate next step in management?
The point: Malaria must be considered in any febrile traveller returning from an endemic area, and the single most important rule is that fever after travel is malaria until proven otherwise. It is caused by Plasmodium species transmitted by mosquitoes; Plasmodium falciparum is the dangerous one, capable of causing severe, rapidly fatal disease, and it usually presents within a month of return, while Plasmodium vivax and ovale can relapse months later from dormant liver forms. The presentation is non-specific: fever, often but not always cyclical, with chills, rigors, sweats, headache, myalgia, and sometimes diarrhoea or jaundice, and examination may show only fever and splenomegaly. The diagnosis rests on thick and thin blood films for the parasite and species with a parasite count, repeated up to three times if the first is negative, supported by rapid antigen tests. Severe falciparum malaria is defined by impaired consciousness, shock, acidosis, hypoglycaemia, severe anaemia, renal failure, pulmonary oedema or a high parasite count, and it is treated as an emergency with parenteral artesunate. Uncomplicated malaria is treated with an appropriate oral regimen by species and resistance, and vivax and ovale need additional treatment to clear the liver stage after checking for G6PD deficiency. Prevention is by bite avoidance and chemoprophylaxis.
Source: Therapeutic Guidelines (Australia) — Antibiotic: malaria Therapeutic Guidelines (Australia) · tier 3, national formulary
Cardiology and vascular · Respiratory · Gastroenterology and hepatology · Renal and urology · Endocrinology and metabolic · Neurology · Haematology · Rheumatology and musculoskeletal · Dermatology · Ophthalmology · Ear, nose and throat · Surgery · Emergency, trauma and toxicology · Women's health · Child health · Mental health · Population health and ethics